FRα : une cible pour la thérapie photodynamique prophylactique des métastases péritonéales ovariennes ?

Azaïs, Henri; Moussaron, Albert; Bach, Sophie; Bassil, Alfred; Betrouni, Nacim; Frochot, Céline; Collinet, Pierre; Mordon, Serge

doi:10.1684/bdc.2014.1977

Cited by 9 publications

(2 citation statements)

References 33 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the standard treatment results in a complete response rate of 40-60%, more than 90% of patients relapse within 18 months and ultimately die from the disease. At present, progress in treating ovarian cancer has increased the median survival from 12 months in the 1970s to more than 65 months in the 2000s [8]. However, there is an urgent need to develop effective approaches to treat peritoneal carcinosis of ovarian origin.…”

Section: Introductionmentioning

confidence: 99%

Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties

Baydoun

Moralès

Frochot

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Often discovered at an advanced stage, ovarian cancer progresses to peritoneal carcinoma, which corresponds to the invasion of the serosa by multiple tumor implants. The current treatment is based on the combination of chemotherapy and tumor cytoreduction surgery. Despite the progress and standardization of surgical techniques combined with effective chemotherapy, post-treatment recurrences affect more than 60% of women in remission. Photodynamic therapy (PDT) has been particularly indicated for the treatment of superficial lesions on large surfaces and appears to be a relevant candidate for the treatment of microscopic intraperitoneal lesions and non-visible lesions. However, the impact of this therapy on immune cells remains unclear. Hence, the objective of this study is to validate the efficacy of a new photosensitizer [pyropheophorbide a-polyethylene glycol-folic acid (PS)] on human ovarian cancer cells and to assess the impact of the secretome of PDT-treated cells on human peripheral blood mononuclear cells (PBMC). We show that PS, upon illumination, can induce cell death of different ovarian tumor cells. Furthermore, PDT using this new PS seems to favor activation of the immune response by inducing the secretion of effective cytokines and inhibiting the pro-inflammatory and immunosuppressive ones, as well as releasing extracellular vesicles (EVs) prone to activating immune cells. Finally, we show that PDT can activate CD4+ and CD8+ T cells, resulting in a potential immunostimulating process. The results of this pilot study therefore indicate that PS-PDT treatment may not only be effective in rapidly and directly destroying target tumor cells but also promote the activation of an effective immune response; notably, by EVs. These data thus open up good prospects for the treatment of micrometastases of intraperitoneal ovarian carcinosis which are currently inoperable.

show abstract

Section: Introductionmentioning

confidence: 99%

Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties

Baydoun

Moralès

Frochot

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Various studies have been initiated to develop folic acid (FA)-conjugated agents for diagnosis by molecular imaging or for the treatment of such diseases [7]. For example, the interest of FA as targeting agent for peritoneal metastasis treatment thanks to Photodynamic Therapy (PDT) has been largely proved by Frochot and coworkers [8][9][10][11][12][13][14][15]. FA can also be an ideal molecule for selective nuclear imaging using FR-targeted radiopharmaceuticals.…”

mentioning

confidence: 99%